<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>艾伯维（AbbVie，股票代码：ABBV）周二表示，已向美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）提交申请，寻求批准 Rinvoq 用于治疗成人和青少年非节段性白癜风（NSV）。</p>
<p>这些申请基于第三阶段 Viti-Up 研究的数据，该研究显示 upadacitinib 在第 48 周达到了至少 50% 的全身再色素化改善和至少 75% 的面部再色素化改善的共同主要终点。</p>
<p>Rinvoq 是一种处方药，已获批准用于多种免疫介导的炎症性疾病，包括类风湿关节炎、克罗恩病和溃疡性结肠炎等。</p>
<p>艾伯维的股票周一收于 225.64 美元，上涨 1.18%。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

<p>艾伯维已向 FDA 和 EMA 提交了申请，寻求批准 Rinvoq 用于治疗成人和青少年的非节段性白癜风。这些申请基于第三阶段 Viti-Up 研究，该研究显示皮肤再色素化有显著改善。Rinvoq 已获批准用于多种免疫介导的炎症性疾病。艾伯维的股价在周一上涨了 1.18%，收于 225.64 美元</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>AbbVie (ABBV) on Tuesday said it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of Rinvoq for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV).</p>
<div class="lb-trans"><p>艾伯维（AbbVie，股票代码：ABBV）周二表示，已向美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）提交申请，寻求批准 Rinvoq 用于治疗成人和青少年非节段性白癜风（NSV）。</p>
</div><p>The submissions are based on data from the Phase 3 Viti-Up studies, which showed that upadacitinib met the co-primary endpoints of at least 50% improvement in total body repigmentation and at least 75% improvement in facial repigmentation from baseline at week 48.</p>
<div class="lb-trans"><p>这些申请基于第三阶段 Viti-Up 研究的数据，该研究显示 upadacitinib 在第 48 周达到了至少 50% 的全身再色素化改善和至少 75% 的面部再色素化改善的共同主要终点。</p>
</div><p>Rinvoq is a prescription medicine approved for a range of immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis among others.</p>
<div class="lb-trans"><p>Rinvoq 是一种处方药，已获批准用于多种免疫介导的炎症性疾病，包括类风湿关节炎、克罗恩病和溃疡性结肠炎等。</p>
</div><p>AbbVie shares closed at $225.64 on Monday, up 1.18%.</p>
<div class="lb-trans"><p>艾伯维的股票周一收于 225.64 美元，上涨 1.18%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

AbbVie Submits Rinvoq For FDA, EMA Approval In Non-Segmental Vitiligo

rttnews

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

艾伯维

Invesco Nasdaq Biotechnology ETF

美国制药 ETF - iShares

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

艾伯维提交 Rinvoq 申请 FDA 和 EMA 批准用于治疗非节段性白癜风